CRB has released an industry report based on survey responses from more than 500 industry leaders and with unique analysis from CRB’s life sciences subject matter experts.
What is in the report?
Warp speed delivery: Speed to market is a more significant business driver in a post “warp speed” delivery environment – even as companies face significant delays in their capital planning strategies. Respondents see essential investment areas for long-range capital planning as manufacturing, research and development, and expansion planning.
Cell and Gene Therapy: Nearly half of the respondents reported plans to move away from autologous cell therapies to focus on modalities with fewer challenges. A large majority intend to continue using viral vector gene technologies in the near term to produce genetically modified cell therapies to ensure quality and reduce operational costs.
Pharma 4.0: Most companies aspire to operate digitally integrated facilities with predictive, real-time analytics within the next one to two years as part of a broader push toward Pharma 4.0. But, they face significant barriers in cost, risk management, and cybersecurity concerns.
Lean Pharma: Dissatisfaction is growing with traditional design-bid-build methods for large capital projects. Companies are “leveraging the predictive capabilities of AI and machine learning to build smarter, more secure, and future-ready manufacturing centers. They’re redesigning the traditional GMP cleanroom to accommodate closed and automated processes—a necessary step toward improving the cost and quality of tomorrow’s medicines,” the report’s authors write.
Sustainability: While the vast majority of respondents said their firms have formalized sustainability metrics or benchmarks at corporate or project levels, capital budgets and questions about the effectiveness of new technologies present stiff challenges.
Oligonucleotides: The responses indicate a rapidly growing interest in the sector including a near-term (1-4 years) focus on capital investment. Newcomers among established biopharmaceutical companies are expected to double their existing contingent, and start-up participation is expected to increase even more steeply.
RNA: Nearly half of the respondents place significant emphasis on RNA-based therapies becoming a major portion of their future pipelines to capitalize on speed-to-market and cost-of-goods advantages.
Read more at www.crbgroup.com.
